Clinical trial
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to…
NCT00025662 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00025662 |
|---|---|
| Title | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS |
| Official title | Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Using "RFT5-SMPT-dgA": Reducing GVHD Risk Associated With Matched, Nonmyeloablative, Stem Cell Transplant for Hematologic Malignancies in Older Adults |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Myelomonocytic, Chronic, Lymphocytic, Lymphoma, Mantle-cell, Non-Hodgkin and 1 more |
| Intervention type | Drug |
| Interventions | RFT5-SMPT-dgA, Isolex system |
| Enrollment | 23 |
| Start date | May 1, 2001 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 28, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: